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Objective: To examine the relationship between osteoarthritis (OA) and type 2 diabetes mellitus (DM).
Methods: OA cartilage from DM and non-DM patients undergoing knee replacement were stimulated by
IL-1b for 24 h and release of interleukin-6 (IL-6) and prostaglandin E2 (PGE2) was measured. Primary
cultured murine chondrocytes were stimulated for 24 and 72 h with or without IL-1b (5 ng/mL) under
normal-glucose (5.5 mM) or high-glucose (25 mM) conditions. The expression and release of pro-
inﬂammatory mediators (IL-6, cyclooxygenase 2 [COX2]/PGE2) were analyzed by quantitative RT-PCR
and ELISA/EIA. Glucose uptake was assessed with (14C)-2-deoxyglucose. Reactive oxygen species (ROS)
and nitric oxide (NO) production were measured. To analyze the mechanism of IL-1b-induced inﬂam-
mation, cells were pretreated or treated with inhibitors of glucose transport (cytochalasin B), the polyol
pathway (epalrestat), mitochondrial oxidative stress (MitoTEMPO) or nitric oxide synthase (L-NAME).
Results: With IL-1b stimulation, IL-6 and PGE2 release was greater in human DM than non-DM OA
cartilage (2.7- and 3-fold, respectively) (P < 0.05). In vitro, with IL-1b stimulation, IL-6 and COX2 mRNA
expression, IL-6 and PGE2 release, and ROS and NO production were greater under high-than normal-
glucose conditions in cultured chondrocytes. IL-1beincreased IL-6 release was reduced with cytochalasin
B, epalrestat, L-NAME or MitoTEMPO treatment (45%, 62%, 38% and 40%, respectively).
Conclusion: OA cartilages from DM patients showed increased responsiveness to IL-1beinduced
inﬂammation. Accordingly, high glucose enhanced IL-1beinduced inﬂammation in cultured chon-
drocytes via oxidative stress and the polyol pathway. High glucose and diabetes may thus participate in
the increased inﬂammation in OA.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is the most frequent age-related joint dis-
ease affecting all tissues in the joint1. The incidence and prevalence
of the disease are increased with speciﬁc risk factors2, with over-
weight and trauma at the forefront. These two risk factors may beF. Berenbaum, Saint-Antoine
du Faubourg Saint-Antoine,
-49-28-25-13.
Berenbaum).
ternational. Published by Elsevier Linvolved in the pathophysiology of the disease by speciﬁc and in-
dependent pathways. Trauma and overweight on weight-bearing
joints provoke local biomechanical stresses; however, recent
studies suggest that a low-grade systemic inﬂammation process
may be involved in some cases such as hand OA, in which obesity
increases the risk by two-fold3,4. More recently, epidemiological
studies have suggested that the OA risk increases with the number
of cardio-metabolic factors, including type 2 diabetes mellitus
(DM)5e8. Moreover, DM independently alters the prognosis by
increasing the risk of total joint replacement9 and could be a spe-
ciﬁc OA risk factor10,11.td. All rights reserved.
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has never been investigated. Overall, explanations regarding any
links between DM and OA remain scarce. Streptozotocin-induced
diabetic rats with insulin deﬁciency and severe hyperglycemia
showed progressive loss of type II collagen and proteoglycans in
cartilage12. At the molecular level, both diseases feature increased
content of interleukin 1b (IL-1b) along with other low-grade in-
ﬂammatory mediators such as IL-6, IL-8, prostaglandin E2 (PGE2) as
well as reactive oxygen species (ROS).
Despite the role of glucose in energymetabolism in all cell types,
including chondrocytes13,14, high glucose concentration may have a
detrimental effect per se because excessive intracellular glucose
concentration can saturate the glycolytic pathway, thereby acti-
vating other secondary pathways involved in glucose metabolism
such as polyol, hexosamine, protein kinase C or pentose phosphate
pathways and producing advanced glycation end products
(AGEs)15. All these pathways are responsible for inducing oxidative
stress, also incriminated in the OA process16. Increased ROS pro-
duction generated by a high-glucose environment is linked to
mitochondrial dysfunction, which may affect cartilage homeo-
stasis16e20. Nitric oxide (NO), the main nitrogen active species
known to have pro-inﬂammatory and pro-degradative effects on
chondrocytes, has been implicated in the pathophysiology of both
DM and OA21e23.
Finally, OA chondrocytes exposed to high glucose were found
unable to down regulate the glucose transporter 1 (GLUT-1), one of
the main glucose transporters expressed in chondrocytes, which
led to enhanced glucose uptake and ROS generation24. However,
the role of high extracellular glucose level on activation of articular
chondrocytes has never been investigated.
To further elucidate the link between DM, chronic hyperglyce-
mia and OA, we aimed to (1) characterize the inﬂammatory proﬁle
of human OA cartilage in patients with and without type 2 DM and
(2) investigate the effect and mechanism of action of high glucose
on chondrocyte activation.Methods
Collection of OA human cartilage
Human OA knee explants were obtained from patients under-
going total joint replacement because of OA at Saint-Antoine Hos-
pital (Paris) shortly after surgery. Informed consent for the use of
tissue and clinical data was obtained from each patient before
surgery. Experiments with human samples were approved by a
French institutional review board (Comite de Protection des Per-
sonnes, Paris Ile de France 5). The diagnosis of knee OA was based
on the American College of Rheumatology criteria25. We pre-
operatively screened patients about their diabetic status using the
medical ﬁle, drugs prescription, and patient interview. For each
diabetic patient included, we matched a non-diabetic patient un-
dergoing total joint replacement because of OA by age and body
mass index (BMI), to avoid confounding factors. All explants from
each patient were manually dissected from all remaining cartilage
zones (i.e., tibial plateaus and femoral condyles) and mixed to
obtain homogenous isolated cartilage samples and managed as
previously described26. Brieﬂy, the cartilage explants were cut into
small pieces (~5 mm3), washed several times with phosphate
buffered saline (PBS) and incubated in DMEM culture medium
containing 25 mM glucose necessary for human explant mainte-
nance, and supplemented with 100 U/mL penicillin, 100 mg/mL
streptomycin, and 4mM glutamine for 24 h at 37Cwith or without
IL-1b (5 ng/mL). Conditioned media (CM) were then collected,
centrifuged (1600 g for 6 min) and stored at 20C. Each volume ofmedium was normalized to wet weight of explants (6 mL/g
tissue)27.
Primary culture of murine articular chondrocytes
Mouse primary chondrocytes were isolated from articular
cartilage of 5-to 6-day-old newborn C57Bl6 mice from Janvier (St
Berthevin, France) and seeded at 8  103 cells per cm as
described28. Articular chondrocytes obtained from newborn mice
using this protocol are considered as relevant to study mature
chondrocytes since type II collagen and aggrecan mRNA levels are
highly expressed while expression of type I collagen mRNA
expression remains low29. After 1 week of ampliﬁcation in DMEM
with 5.5 mM glucose, cells were incubated in serum-free DMEM
(with 5.5mMglucose) containing 0.1% bovine serum albumin (BSA)
for 24 h before treatment (basal experimental medium). Each litter
of mice was used for one experiment. All experiments with murine
articular chondrocytes were performed according to protocols
approved by the French and European ethics committees (Comite
Regional d'Ethique en Experimentation Animale N3 de la region
Ile de France).
Treatment of primary culture of murine chondrocytes
After 24-h incubation in basal experimental medium, murine
chondrocytes were stimulated for 24 or 72 h with IL-1b (5 ng/mL)
(PeproTech, Rocky Hill, NJ, USA) under normal-glucose (5.5 mM) or
high-glucose (25 mM) conditions. Cell lysates were collected for
mRNA extractions and supernatants for assays. The dose of IL-1b
was considered efﬁcient after a dose-effect experiment (data not
shown).
To investigate whether the effect of high glucose was related to
its osmotic effect, cells were incubated with mannitol (19.5 mM)
(SigmaeAldrich, Lyon, France) instead of glucose (25 mM) for 24
and 72 h, with or without IL-1b (5 ng/mL) in 4 separate
experiments.
For mechanistic studies, chondrocytes cultured with normal or
high glucose for 72 h with or without IL-1b (5 ng/mL) were pre-
treated or treated with inhibitors: cytochalasin B (1 mM [Sigma-
eAldrich]), a glucose transporter inhibitor; epalrestat (10 mM
[SigmaeAldrich]), a speciﬁc inhibitor of aldose reductase, the rate
limiting enzyme of the polyol pathway; MitoTEMPO (50 mM [Santa
Cruz Biotechnology, Heidelberg, Germany]), a speciﬁc scavenger of
mitochondrial ROS; or L-NAME, a non-speciﬁc inhibitor of NO
synthase (5 mM [SigmaeAldrich]). The doses of these inhibitors
were chosen according to dose-effect experiment (data not shown)
and literature data.
To analyze the cytotoxic effects of the treatments, we analyzed
cell viability by the Cytotoxicity Detection Kit for Lactate Dehy-
drogenase (LDH) (Roche, Mannheim, Germany). All measurements
were performed in duplicate and the mean of duplicates from one
litter of mice was considered as one experiment, for each condition.
This method of measurement was used for all experiments in this
study.
RNA extraction and quantitative RT-PCR (qRT-PCR)
Total RNA was extracted from chondrocytes with use of the
ReliaPrep RNA Cell Miniprep System kit (Promega, Madison, WI,
USA) and concentrations were determined by spectrophotometry
(Eppendorf, Le Pecq, France). Reverse transcription involved 500 ng
total RNA with the Omniscript RT kit (Qiagen). mRNA levels of IL-6
and cyclooxygenase 2 (COX2) were quantiﬁed with Light Cycler
LC480 (Roche Diagnostics, Indianapolis, IN, USA). PCR ampliﬁcation
conditions were: initial denaturation for 5 min at 95C followed by
Table I
Clinical details and pathological characteristics of patients with osteoarthritis of the
knee with or without type 2 diabetes mellitus
Clinical or pathological
characteristics
Type 2 diabetes
mellitus (n ¼ 5)
Non-type 2
diabetes mellitus
(n ¼ 5)
P
Value
Age (years) 62 ± 7.8 69,6 ± 8.6 0.2934
Female 2 (33%) 3 (60%) 0.5271
Weight (kg) 87.6 ± 15.43 82.6 ± 18.71 >0.99
BMI (kg/m2) 30.6 ± 5.95 29.4 ± 5.46 0.90
Obesity (BMI  30 kg/
m2)
2 (40%) 2 (40%) >0.99
Hypertension 3 (60%) 3 (60%) >0.99
Dyslipidemia 1 (20%) 1 (20%) >0.99
Creatinine level
(mmoL/L)
69 ± 4.6 74.6 ± 24.9 0.88
Fasting plasma glucose
(mmol/L)
7.5 ± 2.0 NA NA
HbA1c (%) 6.27 ± 0.7 NA NA
Treatments Metformin (n ¼ 5),
Sitagliptin (n ¼ 1),
Glimepiride (n ¼ 1),
Gliclazide (n ¼ 1),
Vildagliptin (n ¼ 1)
NA NA
Data are mean ± SD or n (%). BMI ¼ body mass index. HbA1c ¼ hemoglobin A1c.
NA¼ not applicable. All patients had osteoarthritis. Chi-square and ManneWhitney
tests were used for categorical and continuous variables, respectively.
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Product formation was detected at 72C in the ﬂuorescein iso-
thiocyanate channel. Levels of mRNA were normalized to those of
murine hypoxanthine guanine phosphoribosyltransferase (HPRT).
Speciﬁc mouse primer sequences were for IL-6, forward 50-GTCA-
CAGAAGGAGTGGCTA-30, and reverse 50-AGAGAACAACATAAGTCA-
GATACC-30 COX2, forward 50-GTGCCTGGTCTGATGATGTA-30, and
reverse 50-AGTTTGAAGTGGTAACCGC-30; and HPRT, forward 50-
AGGACCTCTCGAAGTGT-30, and reverse 50-ATTCAAATCCCTGAAG-
TACTCAT-30. All measurements were performed in duplicate.
IL-6 and PGE2 production
Murine IL-6 concentration was measured with the Quantikine
enzyme-linked immunosorbent assay (ELISA) kit (R&D systems,
Lille, France). Human IL-6 concentrationwasmeasured in humanCM
with the Pelikine compact kit (Sanquin, Amsterdam, Netherlands).
Murine and human PGE2 concentrations in CMwere measured with
the enzymatic immunoassay (EIA) kit (Cayman Chemical, Ann Arbor,
MI, USA). The limits of detection were 7.8, 0.6 and 7.8 pg/mL,
respectively. All measurements were performed in duplicate.
Glucose uptake
Chondrocytes were seeded and cultured as described above.
After 24-or 72-h stimulationwith orwithout IL-1b under normal-or
high-glucose conditions, cellswerewashed in PBS and incubated for
2 h in a KRP pyruvate buffer 1mM, and pH 7.6 (Hepes 12.5mM, NaCl
120 mM, KCl 5 mM, MgSO4 7H2O 1.2 mM, CaCl2 1 mM, Na2HPO4
1 mM, sodium pyruvate 2 mM, BSA 2%). To analyze the role of
intracellular glucose, glucose transport was inhibited by cytocha-
lasin B (50 mM) added for 20min at 37C. Then, the radioactive 2DG*
mixture (2-deoxy-D-[1-14C]glucose [0.25 mCi/well], cold 2-deoxy-D-
glucose [48 mg/mL] diluted in KRP pyruvate buffer) was added for
incubation for 8 min at 37C. Cells were washed twice in PBS and
incubated in 0.1% SDS for 30min at 22C. Cells lysateswere collected
in a counting vial and rinsed in 500 mL H2O. A volume of 50 mL was
collected for assay of intracellular protein concentration with the
Protein Assay kit (Bio-Rad), and radioactivity (disintegration per
minute)wasmeasured in duplicates by use of a beta counter (Hidex,
Turku, Finland). Data are expressed as disintegrations per min
(DPM) reported for 1 mg intracellular protein. Three separate ex-
periments were performed with three different litters of mice.
Cellular ROS production
Chondrocytes were seeded and cultured as described above in
96-well plates at 1 104 perwell. After 24- and 72-h treatment, ROS
production was measured by ﬂuorometric assay with dichlor-
odihydroﬂuorescein diacetate (DCFDA) (Molecular Probes, Life
Technologies) and colorimetric assay with nitroblue tetrazolium
(NBT) (SigmaeAldrich). For DCFDA assay, which is directly oxidized
by ROS such as superoxide ion, hydrogen peroxide and hydroxyl,
chondrocytes were incubated in obscurity with 17 mM DCFDA for
60min at 37C, thenwashed in PBS, and ﬂuorescencewasmeasured
with the Fluostar Galaxy reader (BMG Labtech, Ortenberg, Ger-
many) at 485 nm excitation and 520 nm emission and analyzed by
use of Biolise (Labsystems, Helsinki, Finland). For NBT assay, which
detects the activity of oxidoreductases, chondrocytes were incu-
batedwith 2mg/mLNBT for 2 h at 37C, in obscurity, then disrupted
with KOH-DMSO, and the amount of coloration was measured by a
spectrophotometer at 560 nm. To normalize the results, intracel-
lular proteins were collectedwith NaOH (0.5M) and concentrations
weremeasured with a spectrophotometer and the Protein Assay kit
(Bio-Rad). ROS concentrations are given as fold induction from thatof the control and by microgram protein. All measurements were
performed in triplicate.
NO release
Nitrite (NO2- ) production was measured by Griess reaction with
the DetectX Nitric Oxide Detection Kit (Arbor Assays, Eisenhower,
Michigan, USA) in CM from chondrocytes treated or not with IL-1b
in normal or high glucose with or without the inhibitor L-NAME.
The nitrite production reﬂects NO production. The sample reacts
with sulphanilamide and N-(1-Naphtyl) ethylenediamine and the
concentration is determined by comparing the optical density at
540 nm in a standard range with minimum detection limit
3.125 mM. Nitrite measurements were performed in duplicate.
Statistical analysis
All data are reported as points representing one single experi-
ment from one litter of mice or one patient with 95% ci. All tests
were non-parametric and were analyzed by use of GraphPad Prism
5 (GraphPad Software, San Diego, CA, USA). The Wilcoxon paired
test was used for all mice experiments and for the human experi-
ments comparing the induction of IL-6 and PGE2 w/o IL-1b. Man-
neWhitney unpaired test was used for the comparison between
non diabetic and diabetic patients. To compare clinical character-
istics of diabetic vs non-diabetic patients, Chi-square test and
ManneWhitney was used for categorical and quantitative vari-
ables, respectively. P  0.05 was considered statistically signiﬁcant.
Results
Increased IL-1beinduced IL-6 and PGE2 production in OA cartilage
from diabetic vs non-diabetic patients
We used 5 cartilage explants from OA type 2 DM patients and 5
from OA non-diabetic patients matched on age and BMI. The dia-
betic and non-diabetic OA patients did not differ in other charac-
teristics, including sex ratio, hypertension, dyslipidemia and
creatininemia (Table I).
Fig. 1. Responsiveness of cartilage explants from osteoarthritic (OA) diabetic and non-diabetic patients to interleukin 1b (IL-1b) stimulation. IL-6 and prostaglandin E2 (PGE2)
release by cartilage explants with or without IL-1b stimulation (5 ng/mL). Each symbol represents a patient, non-diabetic (ND) n ¼ 5 (B) or diabetic (D) n ¼ 5 (C). The bar
represents the mean for each condition and 95% conﬁdence interval is represented. yP ¼ 0.016, *P ¼ 0.03, zP ¼ 0.048.
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analyzed the capacity of explants from diabetic and non-diabetic
patients to release IL-6 and PGE2 in CM after 24-h IL-1b stimula-
tion (5 ng/mL), in similar glucose concentration. First, in the
absence of IL-1b, there was a non-signiﬁcant trend for a sponta-
neous increased production of IL-6 and PGE2 in cartilage from
diabetic and non-diabetic patients (P ¼ 0.15 and 0.27, respectively)
(Fig. 1). Second, after IL-1b stimulation, the release of IL-6 and PGE2
was signiﬁcantly increased in DM and non-DM patients, with
higher levels in diabetic than non-diabetic patients (3-fold for non-
DM against 4.5-fold for DM for IL-6; 1.5-fold for non-DM against
2.7-fold for DM for PGE2) (Fig. 1).Fig. 2. Potentiating effect of high glucose on pro-inﬂammatory induction of murine
normal glucose (5 mM) and high glucose (25 mM) in murine chondrocytes treated with IL-1
IL-6 and cyclooxygenase 2 (COX2) relative to that of hypoxanthine guanine phosphoribosy
condition. Each symbol represents an experiment from one litter of mice in normal glucose
and 95% conﬁdence interval is represented. *P ¼ 0.031.High glucose enhances IL-1b-induced IL-6 and PGE2 production by
murine chondrocytes
Because human OA cartilage explants from DM patients showed
a stronger inﬂammatory phenotype than non-DM cartilage espe-
cially after IL-1b stimulation, we speculated that sustained extra-
cellular high glucose exposure could be one of the actors in this
responsiveness. Thus,weexplored in vitro themechanistic impact of
high glucose on murine chondrocyte activation induced by IL-1b.
Murine cells were treated or not with IL-1b (5 ng/mL) for 24 or 72 h
with normal glucose (5.5 mM) or high glucose (25 mM) (Fig. 2). As
expected, IL-1b increased IL-6mRNA expression and protein releasechondrocytes stimulated with IL-1b. Induction of pro-inﬂammatory mediators with
b (5 ng/mL) at 24 and 72 h. A, Quantitative RT-PCR (qRT-PCR) analysis of mRNA levels of
ltransferase (HPRT), n ¼ 5 for each condition. B, IL-6 and PGE2 release, n ¼ 5 for each
(B) and high glucose (C) conditions. The bar represents the mean for each condition
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glucose concentration [Fig. 2(A) and (B)]. However, with IL-1b
stimulation at 72 h, IL-6 mRNA and protein levels and PGE2 release
were higher with high than normal glucose (4- to 7-fold increase).
At 24 h with IL-1b stimulation, IL-6 mRNA and protein levels and
PGE2 release were higher but not signiﬁcantly, except for COX2
expression which was signiﬁcantly higher with high than normal
glucose. Conversely, high glucose alone (without IL-1b stimulation)
did not change the expression or production of the two pro-
inﬂammatory mediators as compared with normal glucose at 24
and 72 h. Thus, a high-glucose environment enhanced the chon-
drocyte response to IL-1b stimulation after 72 h. Because the effects
of high glucose and IL-1b stimulation were higher at 72 than 24 h,
we chose the longer incubation time for mechanistic experiments.Role of glucose uptake and the polyol pathway in the increased IL-
1b-activated pro-inﬂammatory phenotype induced by high glucose
As a control experiment, we ﬁrst measured glucose uptake in
murine chondrocytes by using 2-deoxyglucose, a non-metabolized
analogue of glucose, with the same experimental schedule
[Fig. 3(A)]. At 24 h, and even more so at 72 h, glucose uptake was
increased with IL-1b treatment under normal-glucose conditions.
Additionally, high glucose further increased glucose uptake, whichFig. 3. Effect of high glucose on radioactive 2-deoxyglucose uptake and of osmotic
stress in murine chondrocytes stimulated with IL-1b. A, Assay of glucose uptake by
murine chondrocytes. Measurement of disintegration per minute (DPM) of the intra-
cellular radioactive 2-deoxyglucose for total intracellular protein, n ¼ 3 for each con-
dition. B, Impact of osmotic stress on the expression of IL-6 by murine chondrocytes
with or without IL-1b stimulation. Cells were incubated with normal glucose (5.5 mM,
B), high glucose (25 mM, C) or mannitol (19.5 mM, ⊗). qRT-PCR analysis of mRNA
levels of IL-6 relative to that of HPRT, n ¼ 4 for each condition. Each symbol represents
an experiment from one litter of mice. The bar represents the mean for each condition.was at its peak rate at 72 h (P for trend ¼ 0.12). Changes in glucose
concentration without IL-1b moderately changed glucose uptake,
which suggests a role for IL-1b in glucose transport variation.
To analyze the possibility that the effect of high glucose level
was due to osmotic stress, we replaced glucose excess (19.5 mM) by
mannitol at the same molar concentration, as a control for the
hyperosmotic effects of high glucose level [Fig. 3(B)]. Chondrocytes
stimulated with IL-1b in the presence of mannitol released
amounts of IL-6 similar to that under normal glucose conditions
(P ¼ 0.12) at 24 and 72 h, but we found a trend for a difference
between expression under high glucose and mannitol (P ¼ 0.06).
Therefore, we could rule out the impact of osmotic stress in the pro-
inﬂammatory effect of high glucose environment.
To determine the direct role of glucose uptake, cells were pre-
treated for 30 min with cytochalasin B (1 mM), a glucose transport
inhibitor [Fig. 4(A)], and IL-6 release was measured. Under normal-
glucose conditions, the IL-1beincreased IL-6 level was notmodiﬁed
by cytochalasin B. Conversely, under high-glucose conditions, the
enhanced IL-6 production was completely blunted as compared
with the normal-glucose condition, which suggests that the
enhanced pro-inﬂammatory phenotype acquired by the chon-
drocytes could result from high glucose uptake.
With increased intracellular glucose, the glycolytic pathway is
saturated, which leads the activated secondary polyol metabolic
pathway15. Aldose reductase and sorbitol deshydrogenase are the
two rate-limiting enzymes in this pathway and transform excessive
glucose into sorbitol and fructose. To address the involvement of the
polyol pathway in the pro-inﬂammatory phenotype of chon-
drocyteswith high glucose,we incubated cellswith orwithout IL-1b
in normal or high glucose for 72 h with a speciﬁc inhibitor of aldose
reductase, epalrestat (10 mM) [Fig. 4(B)]. Under normal glucose,
epalrestat signiﬁcantly decreased the inﬂammatory effect of IL-1b
(28%, P < 0.05). This inhibition was stronger under high glucose,
with a decrease of 62% in IL-6 release with IL-1b stimulation, thus
completely erasing the potentiating effect of high glucose. With
epalrestat treatment, PGE2 production by IL-1b-stimulated chon-
drocytes was similarly reduced (47% and 88% under normal and
high glucose, respectively) (Supplementary Fig. S1).
High glucose increases the oxidative stress induced by IL-1b
To determine whether excess glucose may potentiate chon-
drocyte activation by producing ROS and reactive nitrogen species,
we measured the production of ROS by ﬂuorescent DCFDA
[Fig. 5(A)] and NBT [Fig. 5(B)] and the production of nitrite, as a
reﬂection of NO, by the Griess reaction [Fig. 5(C)]. ROS production
was not modiﬁed with high glucose or IL-1b stimulation separately,
but with IL-1b stimulation and high glucose, ROS production was
enhanced at 24 h and especially at 72 h [Fig. 5(A) and (B)]. IL-1b
stimulated nitrite production whatever the glucose concentration
at 24 and 72 h [Fig. 5(C)]. Interestingly, with IL-1b stimulation, ni-
trite generation was signiﬁcantly higher under high-than normal-
glucose conditions, especially at 72 h. These results stressed the
role of IL-1b and high glucose combined in the formation of
oxidative stress derivatives.
To investigate whether these ﬁndings could be responsible for
the pro-inﬂammatory effect in chondrocytes, cells were treated
with MitoTEMPO (50 mM), a speciﬁc mitochondrial ROS scavenger,
or L-NAME (5 mM), an inhibitor of NO-synthase. LDHmeasurement
revealed no cytotoxic effects at these concentrations (data not
shown). Under normal glucose, neither MitoTEMPO nor L-NAME
modiﬁed IL-1b-increased IL-6 production [Fig. 6(A) and (B)].
However, under high glucose, IL-1b-increased IL-6 production was
inhibited with MitoTEMPO (40%, P ¼ 0.06) and L-NAME (38%;
P < 0.05). In addition, L-NAME but not MitoTempo could inhibit IL-
Fig. 4. Involvement of high glucose uptake and polyol pathway activation in murine chondrocytes stimulated with IL-1b. A, Involvement of glucose uptake on pro-
inﬂammatory chondrocyte activation. Cells were pre-treated for 30 min with cytochalasin B (Cyt; 1 mM). Protein release of IL-6, n ¼ 5 for each condition. B, Involvement of pol-
yol pathway activation in chondrocyte activation with normal or high glucose in IL-1bestimulated murine chondrocytes. Cells were treated with epalrestat (Epal, 10 mM). Protein
release of IL-6, n ¼ 5 for each condition. Each symbol represents an experiment from one litter of mice in normal glucose (B) and high glucose (C) conditions. The bar represents
the mean for each condition and 95% ci is represented.*P ¼ 0.031.
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(Supplementary Fig. S2).
Discussion
To understand the epidemiological link between diabetes
mellitus and OA, we phenotyped OA cartilage from diabetic and
non-diabetic patients according to responsiveness to IL-1b-Fig. 5. Effect of high glucose and pro-inﬂammatory stimulation with IL-1b on gener
production by ﬂuorimetric assay of DCFDA (A) and by colorimetric assay of NBT (B), n ¼ 5 fo
1b at 24 h and at 72 h, for intracellular protein quantity. C, Assay of extracellular nitrite produ
mice in normal glucose (B) and high glucose (C) conditions. The bar represents the meaninduced inﬂammatory stress, as assessed by IL-6 and PGE2 release.
Such increased reactivity was corroborated by sensitization of
articular chondrocytes to a high-glucose environment with IL-1b
stimulation. This enhanced pro-inﬂammatory response under high
glucose conditions was related, at least in part, to increased glucose
uptake, oxidative stress and activation of the polyol pathway and
resulted in a sustained chondrocytic pro-inﬂammatory phenotype
(Fig. 7).ation of oxidative stress reagents by murine chondrocytes. Measurement of ROS
r each condition. Data are fold induction compared to the control condition without IL-
ction, n ¼ 5 for each condition. Each symbol represents an experiment from one litter of
for each condition and 95% conﬁdence interval is represented.*P ¼ 0.031.
Fig. 6. Involvement of high glucose and IL-1b-induced oxidative stress in the pro-
inﬂammatory proﬁle induction of murine chondrocytes. Protein release of IL-6.
Cells were treated with a speciﬁc mitochondrial ROS scavenger, MitoTEMPO (50 mM)
(A, n ¼ 4 for each condition) and an inhibitor of NO-synthase, L-NAME (B, n ¼ 5 for
each condition). Each symbol represents an experiment from one litter of mice in
normal glucose (B) and high glucose (C) conditions. The bar represents the mean for
each condition and 95% conﬁdence interval is represented.*P ¼ 0.031.
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PGE2 by human cartilage from diabetic vs non-diabetic patients
exposed to a high glucose level in the years before arthroplasty.
And, because the low-grade inﬂammation observed in type 2 DM
and OA involves IL-1b, we investigated the inﬂammatory response
of diabetic and non-diabetic OA cartilage to IL-1b. We carefully
selected OA cartilage explants from humans matched on age and
BMI to diabetic patients and found no differences in sex ratio and
other metabolic co-morbidities. All diabetic patients received at
least one anti-diabetic therapy. Unfortunately, we could not analyze
the role of speciﬁc drugs because of lack of statistical power. The
mean values of HbA1c fraction in our patients reﬂects a good gly-
cemia control for the last 3 months before surgery, but does not
reﬂect all the diabetes history and not preclude previous uncon-
trolled DM periods with chronic hyperglycemia. Finally, cartilage
was not histologically scored, but because all patients underwent
total knee replacement, we assume that OA tissular lesions were at
an advanced stage in all cases.
In vitro, we demonstrated increased glucose uptake by articular
chondrocytes under a high-glucose condition, especially with IL-1b
stimulation. IL-1b was already found to increase the synthesis of
the inducible glucose transporters GLUT-1 and -9 in articular
chondrocytes30. We found similar results for GLUT-1 (data not
shown). Thus, under normal-glucose conditions, glucose uptake
was moderately stimulated by IL-1b, despite IL-1beincreasedexpression of GLUT-1. This uptake was markedly increased when
cells were cultured under high-glucose conditions. Treating artic-
ular chondrocytes with cytochalasin B abolished the additive pro-
inﬂammatory effect of high glucose in IL-1-bestimulated chon-
drocytes, which conﬁrms the role of glucose uptake in chondrocyte
activation. Although cytochalasin B is usually used as a glucose
transport inhibitor31, this compound can be responsible for dam-
ages of the microﬁlament network, and thus can alter mechanical
environment of the cell. However, we ﬁrst can observe that cyto-
chalasin B treatment in normal glucose condition, under IL-1b
stimulation, has no effect on IL-6 production, suggesting that
cytochalasin B reverses speciﬁcally the potentiating effect of high
glucose. Second, 2DG* experiments have conﬁrmed that, concom-
itantly to chondrocytes activation, there is an increased glucose
entrance in high glucose condition in presence of IL-1b. We then
can speculate that the effect of cytochalasin B is related here to
glucose uptake effect, not to a global disruption of the microﬁla-
ment network.
Under high-glucose conditions, the glycolytic pathway may be
saturated, for increased ﬂux of available glucose through the alter-
native polyol pathway15. Increased activity of the polyol pathway,
which occurs especially when the glycolytic pathway is saturated by
glucose excess, is an important pathogenic factor in diabetic com-
plications that are beyond glycemic control, because of sorbitol
accumulation32e35. Considering OA as such, we aimed to address the
involvement of this pathway in the potentiation of chondrocyte
activation induced by high glucose. To that end, we treated articular
chondrocyteswith epalrestat, a speciﬁc inhibitor of aldose reductase,
which has had promising results in preventing neuropathy pro-
gression and is currently used in Japan as an oral drug in clinical
practice for this complication36e38. We found a signiﬁcant inhibition
of the potentiating effect of high glucose for both IL-6 and PGE2
production. The production of both mediators was decreased to a
lesser extent under normal glucose conditions when chondrocytes
were treatedwith epalrestat,which suggests that thepolyol pathway
may participate in IL-1b stimulation of chondrocytes by high glucose.
Finally, we studied the impact of high-glucose conditions on
direct synthesis of ROS by articular chondrocytes using 2 different
methods, as well as its potentiating effect on NO production
induced by IL-1b. At 72 h, IL-1b behaved differently under high and
normal glucose conditions and may be responsible for early
oxidative stress only under high glucose, for subsequent IL-6
production.
We used the antioxidant MitoTEMPO and an inhibitor of NO-
synthase, L-NAME. In healthy chondrocytes, the production of en-
ergy from glucose metabolism is mainly from the glycolytic
pathway and mitochondria are poorly solicited39. In a pro-
inﬂammatory and high-glucose environment, the mitochondrial
respiratory chain could be more activated and thus increase mito-
chondrial ROS production. Moreover, superoxide ion (O2-), mainly
produced by mitochondria, is the main product responsible for the
formation of other ROS19. Thus, we treated chondrocytes with a
speciﬁc scavenger of mitochondrial ROS, MitoTEMPO, and found
inhibition of IL-6 production (P ¼ 0.06), which supports that ROS
production induced by high glucose was responsible at least in part
for the production of pro-inﬂammatory mediators. Additionally,
the use of the inhibitor L-NAME suggested the involvement of NO in
the potentiating effect of high glucose in pro-inﬂammatory effects
because we found a signiﬁcant inhibition of IL-6 and PGE2
production.
Excessive production of both superoxyde ion and NO can lead to
peroxynitrite formation, an extremely reactive compound respon-
sible for DNA lesions and lipid peroxidation and thus deleterious for
tissues40,41. This molecule is involved in a wide range of diseases,
including diabetes and OA42,43.
Fig. 7. Hypothetical scheme of high-glucose conditions potentiating the pro-inﬂammatory effect of IL-1b on articular chondrocytes. Under high glucose, glucose uptake is
increased when cells are in a pro-inﬂammatory condition (i.e., IL-1b stimulation) induced by increased expression of glucose transporters GLUT-1 and -9. Intracellular glucose
increase is responsible for the potentiation of the pro-inﬂammatory effect of IL-1b by activating the alternative polyol pathway, the production of mitochondrial ROS and inducible
nitric oxide synthase (iNOS) for the production of NO. This activation leads to IL-6 and PGE2 release.
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cannot exclude that some patients from the non-diabetic group
were undiagnosed. However, including diabetic patients in the
non-diabetic group may underestimate the difference in release of
inﬂammatory mediators.
Second, we performed our mechanistic experiments on primary
cultures of murine but not human chondrocytes. Indeed, to inves-
tigate the effect of glucose and/or IL-1b on chondrocyte activation,
we needed to use normal chondrocytes to rule out the potential
impact of diabetic status. Because of the challenge in obtaining
normal human cartilage explants, we used murine cells. We pre-
viously compared the phenotype of murine and human chon-
drocytes and showed that the main markers of differentiationwere
similar28,29. Moreover, the similarity in terms of IL-6 and PGE2
release by IL-1b-stimulated murine chondrocytes under high
glucose and by diabetic cartilage explants strengthen the use of
murine cells for mechanistic experiments.
Finally, we investigated some pathways involved in the mo-
lecular consequences of glucose excess (i.e., ROS, glucose uptake,
polyol pathway). However, glucose may also act through
numerous other pathways such as the hexosamine pathway,
protein kinase C activation or the production of AGEs, also
involved in the glucotoxicity process seen in DM, but not explored
in the present study15. ROS blockade and polyol inhibition could
prevent reactivity to high glucose, which illustrates their crucial
role in chondrocyte activation due to hyperglycemia. While the
use of antioxidants has led to deceptive results in OA, epalrestat
may be useful in this articular complication of diabetes. The
enhanced degradation of extracellular matrix by the polyol
pathway in intervertebral discs of diabetic rats supports such a
hypothesis44.
Moreover, beyond the effect of high glucose, other molecules
might be involved to explain higher responsiveness of human
cartilage form diabetic patients to inﬂammatory stress. Indeed, type
2 DM is characterized by hyperglycemia, hyperinsulinemia with
insulin resistance and free fatty acids increase45,46. Some studies
have examined the role of insulin in joint tissues and have shown an
anabolic role of this hormone with the induction of the synthesis of
type II collagen and proteoglycans by chondrocytes47e49. However,
the effect of insulin on joint cells and tissues or of insulin resistancein OA needs to be addressed. Activity of the insulin receptor was
found lower in human OA than healthy chondrocytes, which limits
the beneﬁcial effects of this hormone on cells during OA50.
In conclusion, OA cartilages from diabetic patients are more
reactive than non-diabetic to pro-inﬂammatory stress, thus dis-
playing an inﬂammatory phenotype. This phenotype may be due to
glucotoxicity combined with IL1-b stress and then responsible for
sustained inﬂammatory chondrocyte activation involving increased
GLUT expression, glucose uptake, oxidative stress and the polyol
pathway. These results strengthen the hypothesis that diabetes
could be a trigger for the initiation and/or the severity of metabolic
OA and open up the opportunity to prevent OA initiation and/or OA
progression by optimal control of glycemia in this subset of OA
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